Ask AI

Treatment Considerations for a Patient Case Example With Relapsed/Refractory Multiple Myeloma

This activity is available for 0.50 CME/CE credit(s).

Released: December 05, 2025

Expiration: June 04, 2026

See Activity Collection

A patient is referred to you to discuss treatment options for relapsed/refractory (R/R) multiple myeloma (MM). He was initially diagnosed with IgG kappa MM 7 years ago, and previous treatment history includes first-line lenalidomide/bortezomib/dexamethasone with ASCT and lenalidomide maintenance, daratumumab/carfilzomib/dexamethasone, and pomalidomide/cyclophosphamide/dexamethasone.

Interact with our new AI patient case platform to talk about management of a patient with heavily pretreated relapsed/refractory multiple myeloma.

ACTiconsult Relapsed Refractory Myeloma

Pre Assessment: Prepare to Meet Your Patient

Assess your current knowledge and clinical approach before meeting your patient.
1.

How confident are you in evaluating the safety and efficacy data of CAR T-cell and bispecific antibody therapy for the treatment of patients with relapsed/refractory multiple myeloma?

2.

When discussing treatment options with a patient with heavily pretreated relapsed/refractory multiple myeloma, what is a key difference you would tell them about CAR T-cell therapy and bispecific antibody therapy?

3.

You are treating a patient with teclistamab who completed step-up dosing and is on cycle 6 of standard dosing. The patient presents with a new fever and general fatigue. What potential adverse event do you suspect?